Category - Developments

Developments

Evofem Biosciences’ Amphora meets primary and secondary endpoints in Phase 2 trial

Evofem Biosciences (NASDAQ:EVFM) announced positive topline results from its Phase 2b trial evaluating Amphora for the prevention of urogenital chlamydia and gonorrhea in women. The study met its primary and secondary...

December 2, 2019

Developments

Phathom Pharma starts Phase 3 erosive esophagitis trial

Phathom Pharmaceuticals (NASDAQ:PHAT) launched its Phase 3 trial of vonoprazan for the healing and healing maintenance of erosive esophagitis (EE). EE is a type of gastroesophageal reflux disease, or GERD, caused by...

December 2, 2019

Developments

Kamada in pact with Alvotech to commercialization 6 biosimilars in Israel

Kamada (NASDAQ, TASE:KMDA) agreed to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, pending approval of the Israeli Ministry of Health (IMOH). Alvotech’s pipeline includes biosimilar...

December 2, 2019

Developments

Concert starts Phase 2 study of adjunctive schizophrenia therapeutic candidate

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 2 study to evaluate its adjunctive schizophrenia therapeutic candidate, CTP-692, in patients who are stable on an antipsychotic medication. CTP-692 is a deuterium...

December 2, 2019

Developments

Akari reports positive data from long-term Phase 2 nomacopan study

Akari Therapeutics (NASDAQ:AKTX) reported new data from an ongoing, long-term Phase 2 study of nomacopan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement system destroys red blood...

December 2, 2019

Developments

Ventripoint to exhibit new VMS+ 3.0 at radiological conference

Ventripoint Diagnostics (TSXV:VPT; OTCQB:CPTDF) is exhibiting for the first time at the Radiological Society of North America’s scientific assembly and annual meeting in Chicago from Dec. 1 to 6. Ventripoint...

November 29, 2019

Developments

Zenabis completes over-subscribed rights offering

Zenabis Global’s (TSX:ZENA) rights offering was over-subscribed, resulting in the issuance of a maximum of 139,086,624 common shares at a price of 15 cents each for gross proceeds of about $20.8-million. The company is...

November 29, 2019

Developments

FDA accepts Verrica Pharma’s NDA for molluscum contagiosum drug

The FDA accepted Verrica Pharmaceuticals’ (NASDAQ:VRCA) NDA for its molluscum contagiosum drug candidate, VP-102, assigning a PDUFA date of July 13, 2020. VP-102 is a topical cantharidin solution designed to treat...

November 27, 2019

Developments

Journal of Cancer paper identifies TRPV6 as a promising drug target in numerous cancers, including breast, ovarian, prostate and pancreatic cancer

The peer-reviewed Journal of Cancer published a positive review of TRPV6 as a cancer therapy target, supporting the potential of closely-held Soricimed’s lead drug candidate, SOR-C13. TRPV6 plays a role in increasing...

November 26, 2019

Developments

Health Canada approves Profound Medical’s TULSA-PRO system

Health Canada approved the sale of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO system for the ablation of low-to intermediate-risk organ-confined prostate cancer. TULSA-PRO is a transurethral prostate tissue...

November 25, 2019

Category - Developments

Evofem Biosciences’ Amphora meets primary and secondary endpoints in Phase 2 trial

Phathom Pharma starts Phase 3 erosive esophagitis trial

Kamada in pact with Alvotech to commercialization 6 biosimilars in Israel

Concert starts Phase 2 study of adjunctive schizophrenia therapeutic candidate

Akari reports positive data from long-term Phase 2 nomacopan study

Ventripoint to exhibit new VMS+ 3.0 at radiological conference

Zenabis completes over-subscribed rights offering

FDA accepts Verrica Pharma’s NDA for molluscum contagiosum drug

Journal of Cancer paper identifies TRPV6 as a promising drug target in numerous cancers, including breast, ovarian, prostate and pancreatic cancer

Health Canada approves Profound Medical’s TULSA-PRO system

General

More